Results 51 to 60 of about 19,211 (198)

Does Next Generation Sequencing (NGS)‐Based CYP2D6 Sequencing Improve Genotype–Phenotype Concordance in Tamoxifen‐Treated Patients?

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2D6 metabolizes about 20% of commonly used drugs, including tamoxifen, a major hormone therapy for breast cancer. Although the relationship between tamoxifen pharmacokinetics and CYP2D6 genotype has been demonstrated, residual variability in drug exposure remains unexplained.
Jeanne Petit, Julien Plenecassagnes, Aurelie Brice, Florence Dalenc, Ludovic Mallet, Etienne Chatelut, Ayman Al Saati, Fabienne Thomas   +7 more
wiley   +1 more source

Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations

Annals of Human Biology, 2016
Polymorphisms with decreased enzyme activity of their gene products have been reported in region CYP2C with population variations in haplotype structure.To estimate the allelic and genotypic frequencies of variants CYP2C9*2 and CYP2C9*3 and of CYP2C9/CYP2C19 haplotypes in Venezuelan populations.Six hundred and thirty-four individuals from nine admixed ...
Sara Flores-Gutiérrez, Álvaro Rodríguez-Larralde, Merlyn Vívenes de Lugo, Dinorah Castro de Guerra   +3 more
openaire   +3 more sources

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Genotype of cytochrome-450 2C9 in patients with tuberculosis [PDF]

Medičnì Perspektivi, 2013
The aim of present work was to investigate CYP2С9 polymorphism in the south of Ukraine in TB-patients and comparing with the same data of control group by the example of Odessa region. Gene CYP2С9 polymorphism was studied with the help of PCR (polymerase
Kresyun V.I., Filyuk V.V., Antonenko P.B., Rogach K.K., Danylenko Yu.M., Mozolevych G.V.   +5 more
doaj  

Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
A sex‐stratified genome‐wide association study of sulfonylurea response identified sex‐specific genetic loci associated with HbA1c reduction in individuals with type 2 diabetes. Replication and functional validation supported a male‐specific association at the TMEM64/NECAB1 locus, highlighting the potential of sex‐informed pharmacogenomics to advance ...
Joseph H. Breeyear, John S. House, Mark Kvale, Stella Nam, Farida S. Akhtari, Hetal S. Shah, Monique M. Hedderson, Kathleen M. Giacomini, Josyf C. Mychaleckyj, Alessandro Doria, Michael J. Wagner, Josephine H. Li, Sook Wah Yee, John B. Buse, Richard P. Woychik, Daniel M. Rotroff, Alison A. Motsinger‐Reif   +16 more
wiley   +1 more source

DISTRIBUTION OF POLYMORPHISMS OF GENES OF STATINS METABOLISM AND TRANSPORT IN THE LIVER IN PATIENTS WITH CORONARY ARTERY DISEASE ETHNIC UZBEKS WITH SIMVASTATIN INTOLERANCE

Евразийский Кардиологический Журнал, 2017
Background. It is well-known that in majority of cases treatment with statins can be safe and well tolerated, but in some patients observed statin-induced adverse liver or muscle symptoms - the main reasons for statin discontinuation.
A. B. Shek, R. D. Kurbanov, G. J. Abdullayeva, A. V. Nagai, A. A. Abdullaev, S. S. Ahmedova, S. U. Hoshimov, A. V. Ziyaeva   +7 more
doaj   +1 more source

The Effect of Dicloxacillin Administration on Pharmacokinetics of Narrow Therapeutic Window Drugs: Phenytoin and Warfarin

Clinical Pharmacology &Therapeutics, EarlyView.
Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Chanan Shaul, Waseem Mujahed, Ibrahim Idries, Maor Wanounou, Meir Bialer, Yoseph Caraco   +5 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage

Терапевтический архив, 2011
Aim. To investigate frequency of carriage of genetic polymorphisms CYP2C9 and VKORC1 in patients with venous thromboembolic complications (VTEC) in Moscow population given warfarin treatment and effects of this carriage on stability of anticoagulation ...
Natal'ya Mikhaylovna Vorob'eva, Elizaveta Pavlovna Panchenko, Anatoliy Borisovich Dobrovol'skiy, Elena Vladimirovna Titaeva, Zukhra Bilyalovna Khasaeva, Nina Valer'evna Konovalova, Anton Yuvenal'evich Postnov, Aleksandr Ivanovich Kirienko, N M Vorobyeva, E P Panchenko, A B Dobrovolsky, E V Titaeva, Z B Khasaeva, N V Konovalova, A Yu Postnov, A I Kirienko   +15 more
doaj